title: Chelation of gadolinium with deferoxamine in a patient with nephrogenic systemic fibrosis.
abstract: A 65-year-old female with biopsy-confirmed nephrogenic systemic fibrosis (NSF) received a kidney transplantation. Despite good kidney function, her symptoms continued to progress. Deferoxamine was administered intramuscularly at 500 mg/day and later 1000 mg/day after 1 week with no adverse effects. Urine excretion of gadolinium increased from 6.0 μg/day to 11.6 μg/day and subsequently to 13.0 μg/day with 500 mg/day and 1000 mg/day of deferoxamine, respectively. Serum levels, however, remain unchanged from 1.7 ng/ml to 1.4 ng/ml. Although chelation therapy may have a role in the treatment of NSF, deferoxamine is too weak and a stronger chelator is needed.
authors.affiliation: Division of Nephrology and Hypertension.
authors.forename: Nelson
authors.initials: N
authors.lastname: Leung
authors.affiliation: Department of Dermatology.
authors.forename: Mark R
authors.initials: MR
authors.lastname: Pittelkow
authors.affiliation: Department of Radiology.
authors.forename: Christine U
authors.initials: CU
authors.lastname: Lee
authors.affiliation: Department of Laboratory Medicine & Pathology, Mayo Clinic Rochester, Rochester, MN , USA.
authors.forename: Jonathan A
authors.initials: JA
authors.lastname: Good
authors.affiliation: Department of Laboratory Medicine & Pathology, Mayo Clinic Rochester, Rochester, MN , USA.
authors.forename: Matthew M
authors.initials: MM
authors.lastname: Hanley
authors.affiliation: Department of Laboratory Medicine & Pathology, Mayo Clinic Rochester, Rochester, MN , USA.
authors.forename: Thomas P
authors.initials: TP
authors.lastname: Moyer
keywords: chelation; deferoxamine; gadolinium